Personalized treatment of patients with rheumatoid arthritis depending on the T-786С eNOS gene promoter polymorphism and concomitant pathology

Abstract

Purpose: optimization of rheumatoid arthritis treatment depending on the T-786C polymorphism of the eNOS gene promoter and comorbid pathology. Conclusions. Therefore, after the treatment, a decrease in the level of acute-phase indicators of inflammation was observed in all polymorphic variants of the T-786C eNOS gene, but it was the most significant in carriers of the TT genotype.